Cargando…
Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients
BACKGROUND: Alopecia areata (AA) is a chronic autoimmune disorder characterized by patchy loss of hair from scalp, beard, eyebrows, or rarely even body hair. Rarely, the disease can be widespread and severe leading to loss of entire scalp and body hair causing apprehension and psychological stress i...
Autores principales: | Shivanna, Chandrashekar Byalekere, Shenoy, Chaithra, Priya, R Arti |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028993/ https://www.ncbi.nlm.nih.gov/pubmed/30034188 http://dx.doi.org/10.4103/ijt.ijt_21_18 |
Ejemplares similares
-
Role of janus kinase inhibitors in the treatment of alopecia areata
por: Triyangkulsri, Korn, et al.
Publicado: (2018) -
Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
por: Blume-Peytavi, Ulrike, et al.
Publicado: (2015) -
Topical tofacitinib in treatment of alopecia areata
por: Ferreira, Sineida Berbert, et al.
Publicado: (2020) -
Treatment of Resistant Alopecia areata with Tofacitinib
por: Avhad, Ganesh
Publicado: (2022) -
Resistant Alopecia Areata Treated with Tofacitinib
por: Sahay, Govind
Publicado: (2022)